Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Gum Arabic Board is the central authority responsible for the regulation, production, and export of gum arabic from Sudan, which accounts for the majority of the global supply. In the life sciences sector, the board is a critical entity as gum arabic is an essential pharmaceutical excipient used as a stabilizer, emulsifier, and binder in various drug formulations. The board oversees the quality and standardization of Acacia senegal and Acacia seyal resins to meet international pharmacopeia standards. Furthermore, the organization promotes research into the therapeutic benefits of gum arabic, particularly its role as a prebiotic fiber and its potential applications in managing renal and gastrointestinal health. It serves as the primary link between Sudanese producers and the global pharmaceutical and food industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gum Arabic Board.